Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LUNG 
Pulmonx Corp (LUNG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: LUNG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $11.31
1 Year Target Price $11.31
| 4 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.99% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 104.67M USD | Price to earnings Ratio - | 1Y Target Price 11.31 |
Price to earnings Ratio - | 1Y Target Price 11.31 | ||
Volume (30-day avg) 7 | Beta 0.52 | 52 Weeks Range 2.50 - 9.37 | Updated Date 06/29/2025 |
52 Weeks Range 2.50 - 9.37 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -65.27% | Operating Margin (TTM) -64.62% |
Management Effectiveness
Return on Assets (TTM) -22.21% | Return on Equity (TTM) -60.68% |
Valuation
Trailing PE - | Forward PE 28.33 | Enterprise Value 72715282 | Price to Sales(TTM) 1.2 |
Enterprise Value 72715282 | Price to Sales(TTM) 1.2 | ||
Enterprise Value to Revenue 0.83 | Enterprise Value to EBITDA -5.62 | Shares Outstanding 40257500 | Shares Floating 39201169 |
Shares Outstanding 40257500 | Shares Floating 39201169 | ||
Percent Insiders 4.4 | Percent Institutions 93.34 |
Analyst Ratings
Rating 3 | Target Price 11.31 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pulmonx Corp
Company Overview
History and Background
Pulmonx Corp. was founded in 1995. It focuses on developing and commercializing minimally invasive devices for patients with severe lung disease.
Core Business Areas
- Zephyr Valve: The Zephyr Endobronchial Valve is a minimally invasive treatment for severe emphysema, a form of COPD. It is designed to improve breathing by blocking off the most diseased parts of the lung.
Leadership and Structure
Pulmonx is led by CEO, Frederick J. Fischer, and has a standard corporate organizational structure.
Top Products and Market Share
Key Offerings
- Zephyr Endobronchial Valve: The Zephyr Valve is Pulmonx's primary product. It's a minimally invasive treatment for severe emphysema. Market share is estimated around 25% of treatable patients. Revenue from Zephyr valves constitutes the majority of Pulmonx's revenue. Competitors include traditional surgical lung volume reduction and medical management of COPD.
Market Dynamics
Industry Overview
The industry is focused on developing and improving treatments for chronic respiratory diseases, particularly COPD and emphysema. This includes pharmaceuticals, medical devices, and respiratory therapies.
Positioning
Pulmonx is positioned as a leader in minimally invasive treatments for severe emphysema with the Zephyr Valve. Their competitive advantage lies in its proven clinical efficacy and less invasive nature compared to surgery.
Total Addressable Market (TAM)
The TAM for severe emphysema treatments is estimated to be in the billions of dollars. Pulmonx is positioned to capture a significant portion of this TAM through continued adoption of the Zephyr Valve.
Upturn SWOT Analysis
Strengths
- Clinically proven efficacy of Zephyr Valve
- Minimally invasive procedure
- Established market presence in emphysema treatment
- Strong patent protection
Weaknesses
- High cost of the Zephyr Valve procedure
- Dependence on reimbursement approvals
- Relatively small sales force
- Reliance on a single core product
Opportunities
- Expanding indications for the Zephyr Valve
- Increasing awareness of the Zephyr Valve among physicians and patients
- Geographic expansion into new markets
- Development of new products for respiratory diseases
Threats
- Competition from established medical device companies
- Changes in reimbursement policies
- Development of alternative treatments for emphysema
- Potential for adverse events associated with the Zephyr Valve
Competitors and Market Share
Key Competitors
- ABMD
- BSX
- MRK
Competitive Landscape
Pulmonx faces competition from established medical device companies and pharmaceutical companies. Its advantage lies in its focus on minimally invasive treatments for emphysema.
Growth Trajectory and Initiatives
Historical Growth: Pulmonx has experienced revenue growth in recent years, driven by increased adoption of the Zephyr Valve.
Future Projections: Analysts project continued revenue growth for Pulmonx, driven by further market penetration and geographic expansion.
Recent Initiatives: Pulmonx is focused on expanding its sales force, increasing awareness of the Zephyr Valve, and pursuing new clinical studies.
Summary
Pulmonx is a company focused on treating emphysema with its Zephyr Valve. The company's strengths lie in its proven technology, however, it needs to manage cost and reimbursement challenges. They need to keep an eye on competitors and alternative emphysema treatments, as well as global expansion to capture more market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Pulmonx Corp. SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pulmonx Corp
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-10-01 | CEO, President & Director Mr. Steven S. Williamson | ||
Sector Healthcare | Industry Medical Devices | Full time employees 291 | Website https://pulmonx.com |
Full time employees 291 | Website https://pulmonx.com | ||
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.